SEC Form 4 · accession 0001177648-19-000003
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce L A Carter
Director
Period of report
Feb 11, 2019
Accepted (ET)
Feb 13, 2019 · 8:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 11, 2019 | M | 2,734 | $23.40 | A | 2,734 | D | |
| Common StockF2 | Feb 11, 2019 | S | 2,734 | $90.0153 | D | 0 | D | |
| Common Stock | Feb 12, 2019 | M | 5,000 | $23.40 | A | 5,000 | D | |
| Common Stock | Feb 12, 2019 | S | 5,000 | $90.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $23.40 | Feb 11, 2019 | M | 2,734 | D | — | Nov 22, 2023 | Common Stock | 2,734 | 6,546 | D |
| Stock Option (Right to Buy)F3 | $23.40 | Feb 12, 2019 | M | 5,000 | D | — | Nov 22, 2023 | Common Stock | 5,000 | 1,546 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.045, inclusive.
- F3100% of the shares subject to the option are fully vested and exercisable.